Companies Send More Cash Back to Shareholders

Related Link: 

U.S. businesses, under pressure from activist investors, are plowing more cash into dividends and stock buybacks, fueling worries about long-term investment.

Samsung Shuffles Toward a Simpler Structure

Related Link: 

Investors following the reorganization of the Samsung empire should keep their eyes on the electronics prize.

At American Apparel, Suits Overrun the T's

Related Link: 

American Apparel was supposed to be focused by now on fixing its battered business. Instead, its battle to be rid of former CEO Dov Charney has become an unusually protracted battle.

Coke Says It's Ready to Let Monster In

Related Link: 

Coca-Cola is expected to soon close its deal to take a 16.7% stake in energy-drink maker Monster Beverage, but with the purchase comes controversy and litigation.

Boutique Bohemian: High-End Hostels Come to America

Related Link: 

Investors are pouring money into upscale youth hostels, betting the next big market in hospitality will be the scruffy, cost-conscious backpacking crowd.

Apple Set to Issue Yen-Denominated Bonds

Related Link: 

Apple is likely to issue its first yen-denominated bonds in Japan in June, taking advantage of rock-bottom yields.

At These Firms, First Salary Offer Is Final

Related Link: 

Take-it-or-leave-it policies for starting salaries aim to foster transparency, fairness.

Tech Firms Seek Ways to Fend Off Activist Investors

Related Link: 

While some have just surrendered, others are fighting back with tactics like granting founders special stock that gives them control over key decisions.

Calgary's Office Boom Skids on Oil Slump

Related Link: 

When crude prices were high, the commercial real-estate market in Canada’s oil capital rivaled that of Houston. Now energy companies are cutting back, vacating a record amount of space even as construction of nine major buildings is under way.

New Push Ties Cost of Drugs to How Well They Work

Related Link: 

Express Scripts is seeking deals with pharmaceutical companies that would set pricing for some cancer drugs based on how well they work.

Syndicate content